Last reviewed · How we verify
NCT06124846
Determining the Effect of Six Weeks of Cannabis Abstinence on Fronto- Striatal fMRI Markers in Adolescents With Cannabis Use Disorder (ABSCAN)
NA trial testing CB-Abst in Cannabis Use Disorder in 64 participants. Currently enrolling.
15 April 2028
Quick facts
| Lead sponsor | University of Minnesota |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 64 |
| Start date | 1 April 2024 |
| Primary completion | 15 April 2028 |
| Estimated completion | 15 April 2028 |
| Sites | 1 location across United States |
Drugs / interventions tested
- CB-Abst
- CB-Mon
Conditions studied
- Cannabis Use Disorder — all drugs for Cannabis Use Disorder →
Sponsor
University of Minnesota
Who can join
Adults 15 to 18, any sex, with Cannabis Use Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study is to understand the changes in neural correlates of reward in adolescents with and without Cannabis Use Disorder (CUD). The study will collect functional magnetic resonance imaging (fMRI) data at 3 different timepoints with the primary goals of understanding striatal reward-based activation during a Monetary Incentive Delay Task and fronto-striatal fMRI resting-state functional connectivity. The study will also explore self-reported impulsivity. The long-term goal is to advance scientific understanding of neural changes associated with cannabis abstinence and inter-individual variability that cannot be otherwise measured in preexisting observational cohorts such as the Adolescent Brain Cognitive Development Study. This parallel intervention study will collect fMRI data in adolescents ages 15-18 years old with and without CUD at three different timepoints over the course of their intervention. Utilizing a validated paradigm, adolescents with CUD will be randomized to 6-weeks of either incentivized, biochemically verified abstinence via contingency management or monitoring with no required abstinence. Age- and sex-matched adolescents with no lifetime history of cannabis use will also complete the protocol. Participants will complete 9 study visits (3 with fMRI scans) involving urinalysis to confirm cannabis self-report and measures of impulsivity. Participants may additionally and optionally (1) complete daily remote self-report assessments of cannabis use, impulsivity, and mood throughout the 6-week treatment period, and (2) continue participation for an additional 6-week monitoring period after the treatment period, during which they complete daily remote self-report assessments of cannabis use, impulsivity, and mood.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06124846
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cannabis Use Disorder
Currently open trials in the same condition.
- NCT07523633 — Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder · Phase 2 · recruiting
- NCT07056894 — Effects of Action-Based Cognitive Remediation on Substance Misuse in Early Phase Psychosis · NA · recruiting
- NCT07218471 — Cannabis Reduction and Functional Outcomes · NA · recruiting
- NCT07184983 — RS-tDCS for Cannabis Use Disorder: The C.A.R.E.S. Initiative · NA · recruiting
- NCT06883162 — Cannabis-Tobacco Co-Use Treatment Study · Phase 3 · recruiting
Other University of Minnesota trials
Trials by the same sponsor.
- NCT02421497 — MRI Technical Development and Applications in Kidney Disease · not yet recruiting
- NCT04100109 — Evaluating the Metabolic Effects of Polylactose: A Novel Prebiotic · NA · withdrawn
- NCT05454306 — Anser Clavicle Pin for Surgical Management of Midshaft Clavicle Fractures · NA · withdrawn
- NCT03192007 — Multi-Parametric MRI for Renal Transplantation · not yet recruiting
- NCT04940533 — Pharmacokinetics of CFTR Modulators in Pregnant Individuals and in Postpartum Breastfeeding Mothers · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06124846 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Minnesota
- Last refreshed: 7 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06124846.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing